No Data
No Data
Has Suzhou Highfine Biotech Co., Ltd.'s (SZSE:301393) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Haofan Biology (301393.SZ): Has repurchased 0.92% of shares.
On September 3, Geelong announced that as of August 31, 2024, the company had repurchased a total of 998,548 shares through a repurchase dedicated securities account in the centralized competitive trading method, accounting for 0.92% of the company's total share capital. The highest fill price was 51.50 yuan/share, the lowest fill price was 34.78 yuan/share, and the total fill amount was 41.0017 million yuan (excluding transaction fees).
Haofan Biology: 2024 Semi-Annual Report
Haofan Biology: Summary of the 2024 Semi-Annual Report
Haofan Biology (301393.SZ): net income of 65.8091 million yuan in the first half of the year, a year-on-year increase of 12.04%
Geelong reported its semi-annual financial report for 2024 on August 27th. During the reporting period, the revenue was 0.225 billion yuan, a 7.12% year-on-year increase; the net income attributable to shareholders of the listed company was 65.8091 million yuan, a 12.04% year-on-year increase; the net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 59.2825 million yuan, a 6.79% year-on-year increase; basic earnings per share was 0.61 yuan.
Suzhou Highfine Biotech Co., Ltd. (SZSE:301393) CEO Yong Zhu, the Company's Largest Shareholder Sees 11% Reduction in Holdings Value
No Data
No Data